Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 9:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neurocognitive Disorder Clear all
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Examining the Role of Tolerance on Dose-dependent Effects of Acute THC on Oculomotor and Cognitive Performance

NCT06351540
View directory record Official record
Conditions
Cannabis Use, Impaired Driving, Cognitive Impairment
Interventions
Cannabis
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 10, 2026, 9:43 PM EDT
Completed Not applicable Interventional

Old School Hip Hop: Parent Follow-Up & Spanish Speakers Inclusion

NCT06699589
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
Old SCHOOL Hip-Hop (Dementia Education), My Plate (Nutrition Education)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Jun 10, 2026, 9:43 PM EDT
Completed Phase 2 Interventional

GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)

NCT05189210
View directory record Official record
Conditions
Mild to Moderate Alzheimer's Disease
Interventions
GV1001 Placebo, GV1001 0.56mg, GV1001 1.12mg
Drug
Lead sponsor
GemVax & Kael
Industry
Eligibility
55 Years to 85 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Adventura, Florida • Greenacres City, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jun 10, 2026, 9:43 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Juice Plus Supplement Clinical Trial

NCT04656860
View directory record Official record
Conditions
Cognitive Impairment, Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Interventions
Juice Plus+
Dietary Supplement
Lead sponsor
University of Alabama, Tuscaloosa
Other
Eligibility
55 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Jun 10, 2026, 9:43 PM EDT
Active, not recruiting Phase 2 Interventional

The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's

NCT03649724
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Placebo, Eligard 22.5Mg Suspension for Injection
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years to 120 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Boca Raton, Florida • New York, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Jun 10, 2026, 9:43 PM EDT
Completed Phase 2 Interventional

D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients

NCT00047476
View directory record Official record
Conditions
Fatigue, Neoplasms
Interventions
dexmethylphenidate(d-mph)
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
21
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 9:43 PM EDT
Completed Phase 4 Interventional Results available

Trial of Levomilnacipran in Geriatric Depression

NCT02466958
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
levomilnacipran, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Jun 10, 2026, 9:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stanford PIPRA Validation Study in an Elderly Orthopedic Population

NCT06567574
View directory record Official record
Conditions
Delirium, Postoperative Delirium, Cognitive Impairment
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
65 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Jun 10, 2026, 9:43 PM EDT
Completed Phase 2 Interventional Results available

BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

NCT02788513
View directory record Official record
Conditions
Alzheimer Disease
Interventions
BI 425809 dose 1, BI 425809 dose 2, BI 425809 dose 3, BI 425809 dose 4, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
55 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
17
States / cities
Colton, California • Long Beach, California • Redlands, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Jun 10, 2026, 9:43 PM EDT
Completed Phase 4 Interventional Results available

Propofol in Emergence Agitation

NCT00535613
View directory record Official record
Conditions
Emergence Agitation
Interventions
Propofol
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
12 Months to 6 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 20, 2019 · Synced Jun 10, 2026, 9:43 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Terazosin for Dementia With Lewy Bodies

NCT04760860
View directory record Official record
Conditions
Dementia With Lewy Bodies
Interventions
Terazosin Hydrochloride, Placebo
Drug · Other
Lead sponsor
Qiang Zhang
Other
Eligibility
0 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jun 10, 2026, 9:43 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Plasma Hydrogen Sulfide as a Biomarker for Alzheimer's Disease and Related Dementias

NCT05060848
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
Not listed
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
55 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Jun 10, 2026, 9:43 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults

NCT06919926
View directory record Official record
Conditions
Hippocampal Overactivity, Dementia
Interventions
AGB101, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 10, 2026, 9:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Mobile Informatics Solution to Aid in Memory

NCT04700540
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
Smartwatch Reminder (SR) system
Device
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years and older
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Jun 10, 2026, 9:43 PM EDT
Withdrawn Not applicable Interventional

Application of TMS Coupled With VR for Slowing the Rate of Cognitive Decline in Patients With Alzheimer's Disease

NCT04440891
View directory record Official record
Conditions
Alzheimer Disease
Interventions
TMS stimulation with X-Torp task, TMS-Stimulation with MindMotion Go, TMS-Sham with X-Torp task, TMS-Sham with MindMotion Go
Device
Lead sponsor
Ali Rezai
Other
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jun 10, 2026, 9:43 PM EDT
Terminated Phase 3 Interventional Results available

An Open-Label Crenezumab Study in Participants With Alzheimer's Disease

NCT03491150
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Crenezumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Not listed
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
32
States / cities
Newport Beach, California • Redlands, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Jun 10, 2026, 9:43 PM EDT
Completed No phase listed Observational

Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center

NCT01465360
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Vascular Dementia, Fronto-temporal Dementia, Primary Progressive Aphasia, Parkinson' Disease Dementia, Mixed Dementia
Interventions
Not listed
Lead sponsor
Exonhit
Industry
Eligibility
21 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
3
States / cities
Las Vegas, Nevada • Cleveland, Ohio • Lakewood, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 5, 2012 · Synced Jun 10, 2026, 9:43 PM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease

NCT00920946
View directory record Official record
Conditions
Huntington Disease
Interventions
Dimebon, Placebo
Drug · Other
Lead sponsor
Medivation, Inc.
Industry
Eligibility
30 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
24
States / cities
Scottsdale, Arizona • Davis, California • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Jun 10, 2026, 9:43 PM EDT
Completed Phase 2 Interventional

Comparison of MMFS Dosages in Older Adults

NCT03601169
View directory record Official record
Conditions
Anxiety, Depression, Sleep Quality, Cognitive Impairment
Interventions
Low Dose MMFS-205-SR, High Dose MMFS-205-SR, Placebo
Dietary Supplement
Lead sponsor
Neurocentria, Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Jun 10, 2026, 9:43 PM EDT
Completed Not applicable Interventional Results available

Optimizing Function and Independence Through iHI-FIVES

NCT03474380
View directory record Official record
Conditions
Functional Impairment, Cognitive Impairment
Interventions
iHI-FIVES
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
1,406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2024 · Synced Jun 10, 2026, 9:43 PM EDT
Terminated No phase listed Observational

An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US

NCT05097131
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
22
States / cities
Chula Vista, California • Valencia, California • Boca Raton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Jun 10, 2026, 9:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Characterizing and Predicting Drug Effects on Cognition

NCT01889602
View directory record Official record
Conditions
Cognitive Deficits
Interventions
Lorazepam, Placebo, Topiramate 100mg, Topiramate 150mg, Topiramate 200mg
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jun 10, 2026, 9:43 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Determinants of Implementation Success Coordinating Ventilator, Early Ambulation and Rehabilitation Efforts

NCT04249141
View directory record Official record
Conditions
Implementation Science, Delirium, Intensive Care Unit Acquired Weakness, Pain, Sedation Complication, Mechanical Ventilation Complication
Interventions
Survey and concept mapping
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Jun 10, 2026, 9:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Sedation on Cognitive Performance in the Elderly

NCT03089866
View directory record Official record
Conditions
Postoperative Cognitive Dysfunction
Interventions
Midazolam (0.02mg/kg)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jun 10, 2026, 9:43 PM EDT